![]() |
![]() |
|
![]() |
Home | About and More Information | Transporter Data Index |
Transporter | Synonyms | Km (μM) | Cell System | Reference |
---|---|---|---|---|
SLC22A8 | OAT3 | ND | HEK293-OAT3 | Ueo, 2005 |
SLC15A2 | PEPT2 | 72 | MDCK-PEPT2 | Li, 2006 |
Transporter | Synonyms | Inhibitor | IC50 (μM) | Ki (μM) | Substrate used | Cell System | Reference |
---|---|---|---|---|---|---|---|
ABCC2 | MRP2, cMOAT | Cefaclor | >133 | Estradiol-17beta-glucuronide | Sf9 cell membrane vesicles | Morgan, 2013 | |
ABCC3 | MRP3 | Cefaclor | >133 | Estradiol-17beta-glucuronide | Sf9 cell membrane vesicles | Morgan, 2013 | |
ABCC4 | MRP4 | Cefaclor | >133 | Estradiol-17beta-glucuronide | Sf9 cell membrane vesicles | Morgan, 2013 | |
SLC22A8 | OAT3 | Cefaclor | 120.2 | Estrone sulfate | HEK293 cells | Ueo, 2005 | |
SLC15A2 | PEPT2 | Cefaclor | 65 | Glycylsarcosine | MDCK-PEPT2 | Li, 2006 | |
SLC22A6 | OAT1 | Cefaclor | 1095.6 | Para-aminohippurate | HEK293 cells | Ueo, 2005 | |
ABCB11 | BSEP | Cefaclor | >133 | Taurocholate | Sf9 cell membrane vesicles | Morgan, 2013 |
DDI | Implicated Transporter* | Interacting Drug | Affected Drug | AUC | Cmax | CLR | CL/F | t1/2 | Effect on PD | Reference | More Details |
---|---|---|---|---|---|---|---|---|---|---|---|
Clinical PK Impact(fold change) | |||||||||||
1 | OATs | Probenecid | Cefaclor | 2.1 | 1.5 | ND | ND | 1.6 | ND | Welling, 1979 | DDI 1 |
PK = pharmacokinetic
The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
![]() |